These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 20064157

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN.
    Nature; 2002 May 16; 417(6886):254-9. PubMed ID: 12015594
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.
    Al-Shawi R, Tennent GA, Millar DJ, Richard-Londt A, Brandner S, Werring DJ, Simons JP, Pepys MB.
    Open Biol; 2016 Feb 16; 6(2):150202. PubMed ID: 26842068
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis.
    Sahota T, Berges A, Barton S, Cookson L, Zamuner S, Richards D.
    CPT Pharmacometrics Syst Pharmacol; 2015 Feb 16; 4(2):e15. PubMed ID: 26225229
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Immunoradiometric assay for human serum amyloid P component.
    Millar DJ, Hutchinson WL, Pepys MB.
    J Immunol Methods; 2011 Aug 31; 371(1-2):18-24. PubMed ID: 21708157
    [Abstract] [Full Text] [Related]

  • 13. Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis.
    Hachulla E, Maulin L, Deveaux M, Facon T, Blétry O, Vanhille P, Wechsler B, Godeau P, Levesque H, Hatron PY, Huglo D, Devulder B, Marchandise X.
    Am J Med; 1996 Jul 31; 101(1):77-87. PubMed ID: 8686719
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.
    Jager PL, Hazenberg BP, Franssen EJ, Limburg PC, van Rijswijk MH, Piers DA.
    J Nucl Med; 1998 Apr 31; 39(4):699-706. PubMed ID: 9544684
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Novel therapeutic approach to amyloidosis: no implications as yet for patients with Alzheimer's disease].
    Lemstra AW, Eikelenboom P, Meijer EW, van Gool WA.
    Ned Tijdschr Geneeskd; 2002 Sep 14; 146(37):1720-3. PubMed ID: 12357871
    [Abstract] [Full Text] [Related]

  • 20. [At last new light for the treatment of amyloidosis].
    Pettersson T.
    Duodecim; 2003 Sep 14; 119(12):1097-8. PubMed ID: 12868354
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.